In multiple myeloma (MM), neoplastic plasma cells accumulate in the bone marrow where their survival, proliferation, and apoptosis are controlled at multiple levels by interaction with the bone marrow microenvironment. Myeloma cells actively control these interactions by activating stromal and endothelial cells for production of survival factors, such as interleukin-6, and suppressing other cell types such as erythroblasts, normal B cell progenitors, and T-cells. In the present study, we identified primary osteoblasts as additional potential targets for myeloma cellmediated suppression which was partly dependent on the death receptor ligand TRAIL. Besides killing of osteoblasts, myeloma cell lines sensitized osteoblasts to cell death mediated by recombinant TRAIL, whereas primary osteoblasts protected myeloma cells from TRAILmediated apoptosis that was mediated by osteoprotegerin (OPG). Besides increase of osteoclastogenesis and osteoclast activity, suppression of bone-forming cells by myeloma cells might contribute to bone loss in MM patients. In addition, clinical development of recombinant TRAIL as anti-myeloma therapy should include evaluation of potential side effects on viability of normal bone cells.
carcinogenesis, enhanced spontaneous, and experimental tumor metastases has been demonstrated (7) . This clear demonstration of the importance of TRAIL in tumor control as well as its safety profile toward normal tissues raised great hopes of encouraging outcome from early clinical trials.
Despite significant progress in clinical therapy of multiple myeloma, this disease remains incurable by conventional treatment to date. In the search of new treatment strategies, TRAIL has recently been proposed as a candidate agent based on the following preclinical data: Mitsiades et al. (8) presented evidence that TRAIL induced apoptosis in steroid-and chemotherapy-sensitive and resistant multiple myeloma (MM) cell lines. Moreover, the cytotoxic action of TRAIL seemed selective since it spared nonmalignant bone marrow and peripheral blood mononuclear cells while inducing apoptosis of MM tumor (8) . In vivo administration of recombinant TRAIL in a xenograft mice model reduced the growth of established human plasmacytomas (8) . Most importantly, TRAIL-induced apoptosis was not inhibited by IL-6, a potent growth and survival factor for MM cells that blocks various pro-apoptotic signals including Fas ligation (9, 10) . Furthermore, the synergistic action of TRAIL in concert with cytotoxic drugs such as doxorubicin or the proteasome inhibitor PS-341 also suggested its potential clinical value in MM (8) .
Beside the above-mentioned evidence of tumor control by TRAIL + immune cells, there is accumulating evidence that death receptor ligands might also be used by tumor cells themselves to kill bystander cells, a mechanism called "the tumor counter-attack" (11) . Studies from our group revealed that myeloma cells expressed functional Fas ligand (FasL) (12) by which they could kill a Fas-sensitive T cell line in vitro. Erythroblasts were identified as alternate targets for FasL-and/or TRAIL-mediated suppression by myeloma cells (13, 14) . In the present study, we tried to elucidate whether the formation of bone lesions, which develop with high frequency in myeloma patients, is mediated at least in part by interaction of myeloma cells and osteoblasts through FasL and/or TRAIL, thereby inducing cell death in the bone cell fraction. In addition, we addressed the question whether myeloma/osteoblast interactions interfere with the outcome of the therapeutic application of TRAIL in MM.
MATERIALS AND METHODS

Reagents and antibodies
The following reagents and antibodies were used in this study: recombinant human TRAIL ("killer TRAIL," consisting of the extracellular domain of human TRAIL (aa 95-281) fused at the N terminus to a His-tag and a linker peptide); recombinant soluble Fas ligand ("SuperFasL," consisting of the extracellular domain of human FasL (aa 103-281) fused at the N terminus to a linker peptide); recombinant human Fc:TRAIL-R2 (FcDR5); FITC-labeled murine anti-human TRAIL-R1 and -R2 (all from Alexis Corp., Laeufelfingen, Switzerland); PE-labeled murine antihuman TRAIL (Becton-Dickinson, San Diego, CA); antagonistic murine anti-human FasL antibody (clone NOK-1, BD PharMingen, San Diego, CA); and FITC-labeled anti-human Fas (clone UB2, Immunotech, Marseille, France); the long-term labeling fluorescent dye 5-(and-6)-carboxyfluorescein diacetate succinimidyl ester (CFSE, Molecular Probes, Leiden, The Netherlands). Isotype-matched control antibodies for flow cytometric analyses were all purchased from DakoCytomation (Glostrup, Denmark). Recombinant human Fc:CD40 used as negative control for blocking experiments was purchased from Calbiochem (San Diego, CA).
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Bone cells
After obtaining informed patient consent, primary human osteoblasts were isolated from femoral trabecular bone fragments of patients obtained during joint replacement surgery. Specimens of bone were dissected into 2-5 mm pieces and washed thoroughly with phosphate-buffered saline (PBS, pH 7.4) to remove blood cells. Culture of bone fragments were performed at a density of 0.2-0.6 g of tissue per 75 cm 2 culture dishes (Greiner Bio-One GmbH, Frickenhausen, Germany) in Ham-F12 medium (without calcium and phenol red) supplemented with 1.5 g/l sodium bicarbonate (Biochrom AG, Berlin, Germany), 2 mmol/l L-glutamine (GIBCO), and 10% heatinactivated fetal calf serum (PAA Laboratories). Medium was replaced at 3 day intervals. Cells typically reached confluence after 4−6 weeks. Cells were harvested with trypsin/EDTA and subcultured for a maximum of three passages in MEM culture medium supplemented with 1.5 g/l sodium bicarbonate, 0.1 mmol/l nonessential amino acids, 1 mmol/l sodium pyruvate, and 10% FCS. The purity of osteoblast cell cultures yielded from long-term isolation procedures was confirmed using expression of alkaline phosphatase (Sigma, Vienna, Austria) and high intracellular levels of osteocalcin as lineage-specific markers. Osteocalcin was detected by flow cytometry using a specific polyclonal antibody (Chemicon, Temecula, CA).
All cell lines and primary cells were cultured at 37°C in a humidified atmosphere containing 5% CO 2 .
Detection of death receptor/ligand equipment
For detection of surface expression of Fas, FasL, TRAIL-R1, and -R2 and TRAIL, 5 × 10 5 cells were stained for 30 min with specific or isotype control antibodies, washed and immediately analyzed by flow cytometry using a FacsCalibur® flow cytometer (Becton-Dickinson) and the CellQuest® software (Becton-Dickinson). In parallel, intracellular levels of FasL and TRAIL were determined following fixation and permeabilization of cells (Fix and Perm, An der Grub, Kaumberg, Austria). The specific mean fluorescence intensity (MFI) was calculated from the signal ratio of specific to isotype control antibody. A MFI value of ≥1.2 was considered positive. 
Detection
Coculture experiments
For determination of cytotoxic activity of myeloma cells, we performed coculture experiments. Briefly, osteoblasts from individual donors were labeled with 5 µmol/l CFSE for 5 min at 37°C in PBS and the staining procedure was stopped by addition of FCS-containing culture medium. Cells were then washed thoroughly and cocultured with myeloma cells in the absence or presence of specific inhibitors of the Fas or TRAIL-R pathway (i.e., antagonistic anti-FasL antibody, clone NOK-1; recombinant FcDR5). Since primary osteoblasts have a low proliferative activity, CSFE fluorescence intensity stably remains high and allows identification of osteoblasts even following prolonged coculture periods. With the use of the annexinV/PI binding assay and gating on CFSE-labeled cells (channel FL-1), killing of osteoblasts by myeloma cells was quantified.
Statistical methods
For statistical analyses, P values were assessed using the non-parametric Wilcoxon Signed Rank test (StatView 5.1., Abacus Concepts Inc., Berkeley, CA).
RESULTS
Osteoblasts express both Fas and TRAIL-R but are only sensitive to Fas-induced apoptosis
After establishing primary osteoblasts from trabecular bone fragments (n=15), we determined whether these cells express the essential constituents of death receptor signaling, namely Fas and TRAIL-R. Osteoblasts were stained with the specific or negative control antibodies, respectively, and analyzed by flow cytometry. As seen in Fig. 1A , we found high expression of Fas/CD95 and moderate expression of TRAIL-R2/DR5 but failed to detect TRAIL-R1/DR4. Expression of Fas rendered these cells sensitive to apoptosis as detected by an increase in phosphatidylserine exposure following incubation with recombinant soluble FasL (Fig. 1B) . Cytotoxicity of FasL was inhibited by 1h-preincubation with antagonistic FasL antibody NOK-1 (5 µg/ml) before its addition to osteoblast cultures. In contrast, the addition of recombinant human TRAIL had only a minor cytotoxic effect in osteoblasts (Fig. 1B) . The lack of activity was not due to ineffective trimerizing capacity of the recombinant TRAIL used in this study, since it efficiently induced apoptosis in the myeloma cell line RPMI-8226 (see below).
Killing of osteoblasts by myeloma cells is partly mediated by TRAIL
In a previous study, we demonstrated expression of functional FasL on myeloma cell lines and primary neoplastic cells from myeloma patients (12) . These data suggested the ability of myeloma cells to suppress Fas-sensitive target cells, as demonstrated for a T cell line in vitro (12) . Killing of erythroblasts by myeloma cells in a FasL-or TRAIL-mediated manner was observed in later studies (13, 14) . Here, we raised the question whether osteoblasts are targets for death receptor ligand-mediated killing by myeloma cells thereby contributing to bone destruction frequently observed in patients with multiple myeloma. TRAIL expression of the myeloma cell lines used in this study was confirmed by staining cells with anti-TRAIL mab followed by flow cytometric analyses. The expression levels of TRAIL on the cell surface and in intracellular compartments of myeloma cell lines are presented in Table 2 . Osteoblasts were labeled with the cell-permeant cell tracker CFSE and cocultured with unlabeled myeloma cell lines for 72 h at a effector:target ratio of 5:1. We then determined the total fraction of apoptotic osteoblasts, either in early (annexin V+PI−) or late (annexin V+PI+) stage of apoptosis. In the presence of myeloma cells, the percentages of apoptotic osteoblasts increased significantly ( Fig. 2A) . The extent of killing proved to depend on both effector:target ratio (Fig. 2B ) and cultivation time (Fig. 2C ). Osteoblasts clearly died by apoptosis and not by necrosis since we could never detect annexin V−PI+ cells in these coculture experiments. We next raised the question whether target cell killing was mediated by FasL or TRAIL. We therefore included specific inhibitors of FasL and TRAIL, i.e., the antagonistic anti-FasL antibody NOK-1 and the recombinant human Fc:TRAIL-R2 (FcDR5) in the coculture experiments of myeloma cells and osteoblasts. The preincubation of RPMI-8226 cells with anti-FasL was ineffective in blocking killing of osteoblasts (Fig. 3) , while the addition of FcDR5 significantly reduced the percentage of apoptotic osteoblasts (Fig. 3) . Similar results were seen when LP-1 or OPM-2 cells were used as effector cells (Fig. 3 and data not shown). The lacking effect of NOK-1 antibody could not be explained by its inefficient neutralizing activity since it proved to significantly reduce the cytotoxic activity of recombinant soluble FasL (rsFasL, 10 ng/ml) in osteoblasts (Fig. 1B) .
Killing of osteoblasts is mainly mediated by a membrane-bound factor(s)
To determine whether the cytotoxic activity of myeloma cells is mediated by a soluble factor, or whether it is dependent on direct contact between target and effector cells, we separated osteoblasts and myeloma cells during coculture experiments using transwell cell culture inserts with 0.4 µm pore size (Corning, Szabo-Scandic, Austria). As seen in Fig. 4 , induction of apoptosis in osteoblasts by myeloma cells was significantly decreased when direct cell/cell contact of target and effector cells was prevented suggesting that primarily membrane-bound factors are involved in myeloma-mediated cytotoxicity (Fig. 4) .
Increased sensitivity of osteoblasts to recombinant TRAIL in coculture with myeloma cells
A beneficial use of recombinant TRAIL in the therapy of tumor patients has been proposed based on in vitro results demonstrating that it efficiently kills tumor cells while sparing normal cells (3). Since we observed TRAIL-mediated cytotoxicity toward osteoblasts in coculture experiments with myeloma cells (Fig. 2-4) , we next addressed whether recombinant TRAIL would further increase cell death of osteoblasts when cocultured with myeloma cells. Osteoblasts were either cultured alone or in the presence of RPMI-8226 or LP-1 cells for 24 h, followed by addition of recombinant TRAIL (50 ng/ml) for another 24 h. Subsequently, the percentages of apoptotic osteoblasts were determined by the annexinV/PI assay. Osteoblasts were resistant toward TRAIL when cultured alone, while in coculture with RPMI-8226 or LP-1 cells a higher percentage of apoptotic osteoblasts was observed which additionally increased following treatment with recombinant TRAIL (Fig. 5) . Vice versa, RPMI-8226 or LP-1 cells were sensitive to treatment with recombinant TRAIL. Their sensitivity, however, decreased when they were treated in coculture with osteoblasts (Fig. 6) .
Native tumor cells from myeloma patients induce apoptosis in osteoblasts
To address the question whether molecular interactions characterized in the myeloma cell line model in vitro also occur between myeloma cells and osteoblasts in vivo, we cocultured osteoblasts for 72 h with purified CD138+ myeloma cells from patients (n=5). As seen in Table  1 , primary myeloma cells significantly increased the percentage of apoptotic osteoblasts which was significantly blocked by preincubation of myeloma cells with FcDR5.
DISCUSSION
Skeletal complications such as lytic bone lesions, severe bone pain, pathological fractures and hypercalcemia are frequently observed in patients with multiple myeloma. The underlying mechanism responsible for bone lesions in these patients is the increased activity of osteoclasts, the bone-resorbing cells (reviewed in (17)). The osteoclast-activating factors (OAF) have extensively been analyzed and several candidate proteins such as receptor activator of nuclear factor-kappaB ligand (RANKL), MIP1α, IL-1β, IL-6 and tumor necrosis factor-α have been identified (for review see (18)). More recently, gene expression profiling of myeloma cells from patients with or without lytic bone disease revealed no relation between the presence of bone disease and the expression of important osteoclast-activating factors such as RANKL, RANK, osteoprotegerin (OPG), MIP1α, PTHrP and IL1 in myeloma cells (19, 20) . These data suggest that osteoclast activation by the tumor microenvironment and/or additional mechanisms are involved in myeloma cell-induced bone disease (18) .
In normal bone remodeling, osteoclasts resorb old or damaged bone leaving space for osteoblasts to form new bone. Disturbances of this balance in patients with multiple myeloma are further characterized by a marked impairment of bone formation by osteoblasts. Suppression of osteoblasts in myeloma has also been demonstrated by Hjorth-Hansen and coworkers. They used an in vivo model of human myeloma producing bone disease in irradiated severe combined immunodeficiency disease mice and observed the development of a dramatic osteoblastopenia (i.e., a 99% reduction in osteoblast counts; ref 21) . The nature of inhibitors of osteoblast viability and activity in myeloma, however, has largely remained unclear although a role of cytokines and death receptor ligands has been postulated recently (22, 23 ).
An essential role of FasL in bone remodeling has been proposed by Katavic and coworkers (25, 26) who found increased bone mass in gld mice (24) known to have a functional defect in the FasL gene. The increase in bone mass resulted from enhanced bone-forming capacity of osteoblasts and correlated with reduced numbers of apoptotic bone-forming cells detected within the bone, strongly underlining a role of FasL in controlling osteoblast turnover. In view of the fact that myeloma cells express FasL (12) and TRAIL (13) ( Table 2) , it is conceivable that death receptor ligands have a role to play in the suppression of osteoblast activity. Our present study confirms previous reports showing that osteoblasts express Fas (CD95, APO-1) (27) and the death-transducing member of the TRAIL receptors family, namely TRAIL-R2 (28) . In agreement with the latter report, our results demonstrate that primary osteoblasts are insensitive to recombinant TRAIL (28) while they undergo cell death following stimulation with recombinant soluble FasL (Fig. 1B) . Based on these experiments, we first hypothesized that, if myeloma cells kill bone cells, they might do so via FasL but not via TRAIL. However, in coculture with myeloma cells which both expressed FasL (12) and TRAIL (Table 2) , we observed significant killing of osteoblasts which was independent of FasL but partly dependent of TRAIL (Fig. 3) . Beside FasL-mediated escape from immune surveillance of Fas + effectors cells (12) , direct killing of erythroblast precursor cells by FasL and TRAIL (13, 14) , the results of our study now extends the list of potential cellular targets for death receptor ligand-expressing myeloma cells. The ability of the neoplastic cells to kill bone-forming cells by TRAIL might allow them to gain ground within bone necessary for their expansion. Of clinical importance myeloma cell-induced killing of osteoblasts was not limited to myeloma cell lines but could also be observed, when primary myeloma cells were used as effector cells (Table 1) .
Expression of TRAIL in myeloma cells is not part of the neoplastic transformation process, since TRAIL expression has also been demonstrated in normal IL-6-differentiated plasma cells (29) . In these cells, TRAIL mediated killing in an autocrine manner (29) . The presence of TRAIL on the surface of myeloma cells might be deleterious for tumor cell survival in view of their sensitivity to TRAIL-induced cell death observed in vitro. This lethal potential of TRAIL, however, should be counteracted in vivo by constitutive activation of NFκB signaling pathways in the neoplastic clone triggered by their interaction with bone marrow stromal cells (30) . In fact, sensitivity to TRAIL-mediated killing was not observed in resting or activated splenic B-cells (29) characterized by constitutive activation of the NFκB survival pathway (31) . Myeloma cell lines cultured in vitro lacking supportive stimuli from their environment might protect themselves from TRAIL by down-regulating their surface expression, but retaining an intracellular store which can be released at target cell contact (Table 2 ). This might explain our observation that blocking of TRAIL by preincubation of cells with recombinant FcDR5 only partially blocked TRAIL signaling (Fig. 3) .
A killing of osteoblasts independently of FasL was rather unexpected since (1) myeloma cell lines were identical to those used in our previous study in which they killed a T cell line in a FasL-dependent manner (13) and (2) osteoblasts were sensitive to Fas ligation but insensitive to TRAIL-R signaling (Fig. 2) . In view of the rapid convergence of Fas and TRAIL-R signaling into an identical effector pathway of cell death (for review see (32)), the change of sensitivity from Fas to TRAIL-R observed in osteoblasts in our study might be the result of changes in molecules present in the death-inducing signaling complex (DISC). Our data, while excluding TRAIL-R1 or -R2 as possible candidate molecules, since their levels remained unchanged during the coculture period (data not shown), leave the exact nature of the factors involved in this sensitivity switch unclear at present.
All myeloma cell lines used in present study were sensitive to recombinant TRAIL (as representatively shown for RPMI-8226 and LP-1 cells in Fig. 6 ). These data together with results from other groups (8, 33, 34) suggest a potential therapeutic application of TRAIL in multiple myeloma. The concept of death receptor ligands in tumor therapy evolved after the identification of FasL and TRAIL as endogenous cytotoxic weapons of immune effector cells and the detection of their specific receptors on neoplastic cells. However, the fatal outcome of therapies targeting Fas, leading to severe damage of the liver and to death of treated animals (35) , stopped the preclinical development of FasL as therapeutic tool for tumor therapy. A new hope for the applicability of death receptor ligands in tumor therapy arose from observations made by several groups that TRAIL, a further member of the TNF family, selectively killed tumor cells and was nontoxic to the majority to normal cell types (3, 36) . The results of our study now show that normal tissues might be sensitized to the cytotoxic action of TRAIL by the neoplastic clone itself. In our experiments, we used primary osteoblasts from healthy donors. Their short cocultivation with myeloma cells rendered them sensitive to TRAIL's cytotoxic action. This cytotoxicity could not be explained by the fact that we used a tagged version of TRAIL in our study, because this version of TRAIL failed to kill normal osteoblasts when they were cultured alone (Figs. 1 and 5) . Instead, sensitivity of osteoblasts to TRAIL signaling was found to increase in the presence of myeloma cells (Fig. 5 ) whereas myeloma cells were less sensitive to recombinant TRAIL in coculture with osteoblasts (Fig. 6) . Thus, the efficacy of TRAIL in a therapeutic setting might be reduced in myeloma patients by a protective factor produced by osteoblasts. Osteoprotegerin should fulfill all criteria of such a factor, since it has been shown to be produced by osteoblasts and stromal cells, and to block TRAIL-induced apoptosis in myeloma cells (37) . In fact, addition of recombinant OPGL, which represents the high-affinity ligand of OPG and is able to decrease binding of OPG to TRAIL (37), could revert the protective effect of osteoblasts on TRAIL-induced apoptosis in myeloma (Fig. 6 ).
In conclusion, the results of our study revealed a role of TRAIL in the inhibition of bone formation in multiple myeloma. The identification of molecular mechanisms involved in sensitization of osteoblasts and desensitization of myeloma cells to TRAIL signaling might be a prerequisite for safety and efficacy of TRAIL in myeloma therapy. stained with respective specific antibodies for TRAIL-R1 (DR4), TRAIL-R2 (DR5), or Fas, washed, and analyzed immediately by flow cytometry. As negative control, isotype-matched control antibodies were used. Mean specific fluorescence intensity representing the ratio of specific and background signal intensities is presented in box-and-whiskers plots. B) Primary osteoblasts are sensitive to Fas-but not to TRAIL-R-induced apoptosis. Primary human osteoblasts of healthy donors (n=15) were cultured for 24 h in the absence or presence of the agonistic recombinant soluble Fas ligand (rsFasL, 10 ng/ml) or recombinant TRAIL (rsTRAIL, 50 ng/ml), respectively. Percentages of apoptotic cells were determined using the annexinV-Alexa647/PI binding assay. Cytotoxic activity of recombinant soluble FasL was inhibited by 1 h preincubation with antagonistic FasL antibody NOK-1 (5 µg/ml) before its addition to osteoblast cultures. 
